Invited review. Series: Implications of the recent CVOTs in type 2 diabetes

Large cardiovascular outcome trials (CVOTs) have lent support to a cardiovascular protection with the use of SGLT2-inhibitors (SGLT2is) and GLP1-Receptor Agonists (GLP1-RAs) in subjects with type 2 diabetes. These two classes of novel glucose lowering agents have been shown to have a similar effect on the risk reduction of Major Adverse Cardiovascular Events (MACE: nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality). Nonetheless, they may not be simply interchangeable. Rather, careful evaluation of all the results of CVOTs allows identification of different effects that may allow profiling of the ideal individuals with T2DM who may benefit most from the use of one or the other class of agents.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research